List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8192674/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ZFP36L2 suppresses mTORc1 through a P53-dependent pathway to prevent peripartum cardiomyopathy in mice. Journal of Clinical Investigation, 2022, 132, .	8.2	8
2	Interleukin-1α dependent survival of cardiac fibroblasts is associated with StAR/STARD1 expression and improved cardiac remodeling and function after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2021, 155, 125-137.	1.9	6
3	Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation. Circulation, 2021, 143, 2475-2493.	1.6	99
4	Automated processing of thermal imaging to detect COVID-19. Scientific Reports, 2021, 11, 17489.	3.3	25
5	Response by Leor et al to Letter Regarding Article, "Extracellular Vesicles From Epicardial Fat Facilitate Atrial Fibrillation― Circulation, 2021, 144, e282.	1.6	1
6	Automated thermal imaging for the detection of fatty liver disease. Scientific Reports, 2020, 10, 15532.	3.3	17
7	Nitroxideâ€enhanced MRI of cardiovascular oxidative stress. NMR in Biomedicine, 2020, 33, e4359.	2.8	7
8	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. Cardiovascular Research, 2019, 115, 488-500.	3.8	90
9	Response by Naftali-Shani et al to Letter Regarding Article, "Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes― Circulation, 2019, 139, e992-e993.	1.6	0
10	Non-invasive thermal imaging of cardiac remodeling in mice. Biomedical Optics Express, 2019, 10, 6189.	2.9	12
11	Abstract 719: CRISPR/Cas9- Based Knockout of the TLR4 gene Enhances Secretion of Extracellular Vesicles With Anti-Inflammatory Properties From Human Cardiac Mesenchymal Stromal Cells. Circulation Research, 2019, 125, .	4.5	0
12	Beneficial Effect of the SGLT2 Inhibitor Empagliflozin on Glucose Homeostasis and Cardiovascular Parameters in the Cohen Rosenthal Diabetic Hypertensive (CRDH) Rat. Journal of Cardiovascular Pharmacology and Therapeutics, 2018, 23, 358-371.	2.0	16
13	Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 19-34.	3.8	284
14	Modeling Peripartum Cardiomyopathy With Human Induced Pluripotent Stem Cells Reveals Distinctive Abnormal Function of Cardiomyocytes. Circulation, 2018, 138, 2721-2723.	1.6	9
15	E-selectin-targeted copolymer reduces atherosclerotic lesions, adverse cardiac remodeling, and dysfunction. Journal of Controlled Release, 2018, 288, 136-147.	9.9	31
16	SIRT6 Overexpression Improves Various Aspects of Mouse Healthspan. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2017, 72, glw152.	3.6	32
17	In vivo comparative study of distinct polymeric architectures bearing a combination of paclitaxel and doxorubicin at a synergistic ratio. Journal of Controlled Release, 2017, 257, 118-131.	9.9	48
18	Loss of Macrophage Wnt Secretion Improves Remodeling and Function After Myocardial Infarction in Mice. Journal of the American Heart Association, 2017, 6, .	3.7	55

#	Article	IF	CITATIONS
19	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	3.8	114
20	The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study. Cardiovascular Diabetology, 2017, 16, 69.	6.8	23
21	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 564-585.	3.8	278
22	Left Ventricular Dysfunction Switches Mesenchymal Stromal Cells Toward an Inflammatory Phenotype and Impairs Their Reparative Properties Via Toll-Like Receptor-4. Circulation, 2017, 135, 2271-2287.	1.6	53
23	Targeting and modulating infarct macrophages with hemin formulated in designed lipid-based particles improves cardiac remodeling and function. Journal of Controlled Release, 2017, 257, 21-31.	9.9	34
24	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. Cardiovascular Research, 2017, 113, 1418-1419.	3.8	11
25	Addition of beta-blockers to digoxin is associated with improved 1- and 10-year survival of patients hospitalized due to decompensated heart failure. International Journal of Cardiology, 2016, 221, 198-204.	1.7	5
26	Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. European Heart Journal, 2016, 37, 1789-1798.	2.2	210
27	Macrophages and regeneration: Lessons from the heart. Seminars in Cell and Developmental Biology, 2016, 58, 26-33.	5.0	30
28	Macrophages dictate the progression and manifestation of hypertensive heart disease. International Journal of Cardiology, 2016, 203, 381-395.	1.7	52
29	Optimization of Irreversible Electroporation Protocols for In-vivo Myocardial Decellularization. PLoS ONE, 2016, 11, e0165475.	2.5	49
30	The Type of Injury Dictates the Mode of Repair in Neonatal and Adult Heart. Journal of the American Heart Association, 2015, 4, e001320.	3.7	44
31	A comparative study of folate receptor-targeted doxorubicin delivery systems: Dosing regimens and therapeutic index. Journal of Controlled Release, 2015, 208, 106-120.	9.9	66
32	ERBB2 triggers mammalian heart regeneration byÂpromoting cardiomyocyte dedifferentiation andÂproliferation. Nature Cell Biology, 2015, 17, 627-638.	10.3	541
33	Targeting Macrophage Subsets for Infarct Repair. Journal of Cardiovascular Pharmacology and Therapeutics, 2015, 20, 36-51.	2.0	75
34	Injectable Collagen Implant Improves Survival, Cardiac Remodeling, and Function in the Early Period After Myocarditis in Rats. Journal of Cardiovascular Pharmacology and Therapeutics, 2014, 19, 470-480.	2.0	10
35	Intracoronary Delivery of Injectable Bioabsorbable Scaffold (IK-5001) to Treat Left Ventricular Remodeling After ST-Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2014, 7, 806-812.	3.9	122
36	Multi-Investigator Letter on Reproducibility of Neonatal Heart Regeneration following Apical Resection. Stem Cell Reports, 2014, 3, 1.	4.8	65

#	Article	IF	CITATIONS
37	The autoimmune side of rheumatic fever. Israel Medical Association Journal, 2014, 16, 654-5.	0.1	9
38	Human Macrophage Regulation Via Interaction With Cardiac Adipose Tissue-Derived Mesenchymal Stromal Cells. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 78-86.	2.0	78
39	Macrophage Subpopulations Are Essential for Infarct Repair With and Without Stem Cell Therapy. Journal of the American College of Cardiology, 2013, 62, 1890-1901.	2.8	215
40	Percutaneous revascularization and long term clinical outcomes of diabetic patients randomized in the Occluded Artery Trial (OAT). International Journal of Cardiology, 2013, 168, 2416-2422.	1.7	10
41	The Origin of Human Mesenchymal Stromal Cells Dictates Their Reparative Properties. Journal of the American Heart Association, 2013, 2, e000253.	3.7	41
42	Mast Cell Inhibition Attenuates Myocardial Damage, Adverse Remodeling, and Dysfunction During Fulminant Myocarditis in the Rat. Journal of Cardiovascular Pharmacology and Therapeutics, 2013, 18, 152-161.	2.0	19
43	Monocyte and/or Macrophage Infiltration of Heart after Myocardial Infarction: MR Imaging by Using T1-shortening Liposomes. Radiology, 2012, 264, 428-435.	7.3	47
44	Molecular Imaging of Healing After Myocardial Infarction. Current Cardiovascular Imaging Reports, 2011, 4, 63-76.	0.6	13
45	The effect of immobilized RGD peptide in alginate scaffolds on cardiac tissue engineering. Acta Biomaterialia, 2011, 7, 152-162.	8.3	211
46	The promotion of myocardial repair by the sequential delivery of IGF-1 and HGF from an injectable alginate biomaterial in a model of acute myocardial infarction. Biomaterials, 2011, 32, 565-578.	11.4	260
47	Modulation of cardiac macrophages by phosphatidylserine-presenting liposomes improves infarct repair. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 1827-1832.	7.1	301
48	The effects of controlled HGF delivery from an affinity-binding alginate biomaterial on angiogenesis and blood perfusion in a hindlimb ischemia model. Biomaterials, 2010, 31, 4573-4582.	11.4	148
49	Prevascularization of cardiac patch on the omentum improves its therapeutic outcome. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 14990-14995.	7.1	325
50	Patient Characteristics and Cell Source Determine the Number of Isolated Human Cardiac Progenitor Cells. Circulation, 2009, 120, 2559-2566.	1.6	125
51	The effects of peptide-based modification of alginate on left ventricular remodeling and function after myocardial infarction. Biomaterials, 2009, 30, 189-195.	11.4	136
52	Intracoronary Injection of In Situ Forming Alginate Hydrogel Reverses Left Ventricular Remodeling After Myocardial Infarction in Swine. Journal of the American College of Cardiology, 2009, 54, 1014-1023.	2.8	308
53	Evaluation of a Peritoneal-Generated Cardiac Patch in a Rat Model of Heterotopic Heart Transplantation. Cell Transplantation, 2009, 18, 275-282.	2.5	31
54	Predictors of Outcome and the Lack of Effect of Percutaneous Coronary Intervention Across the Risk Strata in Patients With Persistent Total Occlusion After Myocardial Infarction. JACC: Cardiovascular Interventions, 2008, 1, 511-520.	2.9	15

#	Article	IF	CITATIONS
55	Irreversible Electroporation Attenuates Neointimal Formation After Angioplasty. IEEE Transactions on Biomedical Engineering, 2008, 55, 2268-2274.	4.2	39
56	Effect of Bundle Branch Block Patterns on Mortality in Hospitalized Patients With Heart Failure. American Journal of Cardiology, 2008, 101, 1303-1308.	1.6	21
57	Myocardial repair: from salvage to tissue reconstruction. Expert Review of Cardiovascular Therapy, 2008, 6, 669-686.	1.5	37
58	Effect of Injectable Alginate Implant on Cardiac Remodeling and Function After Recent and Old Infarcts in Rat. Circulation, 2008, 117, 1388-1396.	1.6	406
59	Prevalence and significance of unrecognized renal insufficiency in patients with heart failure. European Heart Journal, 2008, 29, 1029-1036.	2.2	35
60	Pheochromocytoma: cyclic attacks of hypertension alternating with hypotension. Nature Clinical Practice Cardiovascular Medicine, 2008, 5, 53-57.	3.3	28
61	Response to Letter Regarding Article, "Iron-Oxide Labeling and Outcome of Transplanted Mesenchymal Stem Cells in the Infarcted Myocardium― Circulation, 2008, 117, .	1.6	1
62	Umbilical Cord Blood Cells for Cardiac Repair. , 2008, , 59-72.		0
63	Human embryonic stem cell transplantation to repair the infarcted myocardium. Heart, 2007, 93, 1278-1284.	2.9	183
64	The Effect of Irreversible Electroporation on Blood Vessels. Technology in Cancer Research and Treatment, 2007, 6, 307-312.	1.9	300
65	Trends in Management, Hospital and Long-Term Outcomes of Elderly Patients with Acute Myocardial Infarction. American Journal of Medicine, 2007, 120, 90-97.	1.5	13
66	The management, early and one year outcome in hospitalized patients with heart failure: a national Heart Failure Survey in IsraelHFSIS 2003. Israel Medical Association Journal, 2007, 9, 227-33.	0.1	26
67	Late mortality and determinants in patients with heart failure and preserved systolic left ventricular function: the Israel Nationwide Heart Failure Survey. Israel Medical Association Journal, 2007, 9, 234-8.	0.1	13
68	Autospecies and Post–Myocardial Infarction Sera Enhance the Viability, Proliferation, and Maturation of 3D Cardiac Cell Culture. Tissue Engineering, 2006, 12, 3467-3475.	4.6	15
69	Coronary Intervention for Persistent Occlusion after Myocardial Infarction. New England Journal of Medicine, 2006, 355, 2395-2407.	27.0	635
70	Influence of the new definition of acute myocardial infarction on coronary care unit admission, discharge diagnosis, management and outcome in patients with non-ST elevation acute coronary syndromes: A national survey. International Journal of Cardiology, 2006, 106, 164-169.	1.7	15
71	Evaluation of the pro-angiogenic effect of factor XIII in heterotopic mouse heart allografts and FXIII-deficient mice. Thrombosis and Haemostasis, 2006, 95, 546-550.	3.4	30
72	Human Umbilical Cord Blood-Derived CD133+Cells Enhance Function and Repair of the Infarcted Myocardium. Stem Cells, 2006, 24, 772-780.	3.2	121

#	Article	IF	CITATIONS
73	Renovation of the injured heart with myocardial tissue engineering. Expert Review of Cardiovascular Therapy, 2006, 4, 239-252.	1.5	43
74	Cells, scaffolds, and molecules for myocardial tissue engineering. , 2005, 105, 151-163.		302
75	Effect of Matrix Metalloproteinase Inhibition by Doxycycline on Myocardial Healing and Remodeling after Myocardial Infarction. Cardiovascular Drugs and Therapy, 2005, 19, 383-390.	2.6	38
76	Cancer Cells Ablation with Irreversible Electroporation. Technology in Cancer Research and Treatment, 2005, 4, 699-705.	1.9	261
77	Recommendations for the structure, organization, and operation of intensive cardiac care units. European Heart Journal, 2005, 26, 1676-1682.	2.2	94
78	Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. European Heart Journal, 2005, 26, 2032-2038.	2.2	83
79	Presenting Symptoms, Admission Electrocardiogram, Management, and Prognosis in Acute Coronary Syndromes: Differences by Age. The American Journal of Geriatric Cardiology, 2004, 13, 188-196.	0.6	36
80	Peroxisome Proliferator–Activated Receptor Ligand Bezafibrate for Prevention of Type 2 Diabetes Mellitus in Patients With Coronary Artery Disease. Circulation, 2004, 109, 2197-2202.	1.6	157
81	Myocardial Tissue Engineering: Creating a Muscle Patch for a Wounded Heart. Annals of the New York Academy of Sciences, 2004, 1015, 312-319.	3.8	74
82	Prolonged 24-hour subzero preservation of heterotopically transplanted rat hearts using antifreeze proteins derived from arctic fish. Annals of Thoracic Surgery, 2004, 77, 1648-1655.	1.3	44
83	Evaluation of Pro-Angiogenic Activity of Factor XIII (FXIII) in Ischemic Tissue, Heart Transplantation and FXIII-Deficient Mice Blood, 2004, 104, 2987-2987.	1.4	1
84	Ex-Vivo Expanded Human Bone Marrow-Derived AC133+ Cells To Treat Myocardial Infarction Blood, 2004, 104, 154-154.	1.4	0
85	Rebuilding broken hearts. Biologists and engineers working together in the fledgling field of tissue engineering are within reach of one of their greatest goals: constructing a living human heart patch. Scientific American, 2004, 291, 44-51.	1.0	10
86	Reprogramming cells for transplantation. Heart Failure Reviews, 2003, 8, 285-292.	3.9	8
87	Editorial: regeneration hope to grow a new heart muscle. Heart Failure Reviews, 2003, 8, 197-199.	3.9	2
88	Cardiomyocyte transplantation into the failing heart-new therapeutic approach for heart failure?. Heart Failure Reviews, 2003, 8, 201-211.	3.9	31
89	Refractoriness and conduction interaction during modulation of non-ischemic ventricular fibrillation by flecainide. Cardiovascular Drugs and Therapy, 2003, 17, 237-247.	2.6	1
90	Comparison of effectiveness of angiotensin-converting enzyme inhibitors after acute myocardial infarction in diabetic versusnondiabetic patients. American Journal of Cardiology, 2003, 92, 1020-1025.	1.6	12

#	Article	IF	CITATIONS
91	Systemic Delivery of Bone Marrow–Derived Mesenchymal Stem Cells to the Infarcted Myocardium. Circulation, 2003, 108, 863-868.	1.6	1,115
92	Functional class in patients with heart failure is associated with the development of diabetes. American Journal of Medicine, 2003, 114, 271-275.	1.5	90
93	Cell transplantation and genetic engineering: new approaches to cardiac pathology. Expert Opinion on Biological Therapy, 2003, 3, 1023-1039.	3.1	8
94	Modulation of Ventricular Fibrillation in Isolated Perfused Heart by Dofetilide. Journal of Cardiovascular Pharmacology, 2003, 41, 838-848.	1.9	2
95	Soluble intercellular adhesion molecule-1 and long-term risk of acute coronary events in patients with chronic coronary heart disease. Journal of the American College of Cardiology, 2002, 39, 1133-1138.	2.8	90
96	Timing of aspirin administration as a determinant of survival of patients with acute myocardial infarction treated with thrombolysis. American Journal of Cardiology, 2002, 89, 381-385.	1.6	82
97	Status of glucose metabolism in patients with heart failure secondary to coronary artery disease. American Journal of Cardiology, 2002, 90, 529-532.	1.6	12
98	Optimization of cardiac cell seeding and distribution in 3D porous alginate scaffolds. Biotechnology and Bioengineering, 2002, 80, 305-312.	3.3	363
99	Effects of adrenaline on electrophysiological parameters during short exposure to global ischemia. A ventricular fibrillation study in isolated heart. Cardiovascular Drugs and Therapy, 2002, 16, 111-119.	2.6	3
100	Influence of Embryonic Cardiomyocyte Transplantation on the Progression of Heart Failure in a Rat Model of Extensive Myocardial Infarction. Journal of Molecular and Cellular Cardiology, 2001, 33, 1321-1330.	1.9	196
101	Myocardial Regeneration. American Journal of Cardiovascular Drugs, 2001, 1, 233-244.	2.2	30
102	Aspirin and ACE-inhibitors: for wedding or funeral?. Journal of Thrombosis and Thrombolysis, 2001, 11, 163-169.	2.1	1
103	Usefulness of pre- versus postadmission cardiogenic shock during acute myocardial infarction in predicting survival. American Journal of Cardiology, 2001, 87, 1200-1203.	1.6	4
104	Effect on survival of acute myocardial infarction in Killip classes II or III patients undergoing invasive coronary procedures. American Journal of Cardiology, 2001, 88, 618-623.	1.6	23
105	Possible Interaction Between Aspirin and ACE Inhibitors: Update on Unresolved Controversy. Congestive Heart Failure, 2000, 6, 313-318.	2.0	7
106	Breast artery calcium on routine mammography as a potential marker for increased risk of cardiovascular disease. American Journal of Cardiology, 2000, 86, 216-217.	1.6	63
107	Sex Differences in Management and Outcome After Acute Myocardial Infarction in the 1990s. Circulation, 2000, 102, 2484-2490.	1.6	150
108	Cytotoxic T Lymphocytes Are Activated Following Myocardial Infarction and Can Recognize and Kill Healthy Myocytes In Vitro. Journal of Molecular and Cellular Cardiology, 2000, 32, 2141-2149.	1.9	127

#	Article	IF	CITATIONS
109	Aspirin and mortality in patients treated with angiotensin-converting enzyme inhibitors. Journal of the American College of Cardiology, 1999, 33, 1920-1925.	2.8	93
110	Platelet-activating factor and cardiac diseases: therapeutic potential for PAF inhibitors. Journal of Lipid Mediators and Cell Signalling, 1997, 15, 255-284.	0.9	26
111	Population-Based Analysis of the Effect of the Northridge Earthquake on Cardiac Death in Los Angeles County, California. Journal of the American College of Cardiology, 1997, 30, 1174-1180.	2.8	147
112	Pathobiology and Clinical Impact of Reperfusion Injury. Journal of Thrombosis and Thrombolysis, 1997, 4, 185-195.	2.1	10
113	Sudden Cardiac Death Triggered by an Earthquake. New England Journal of Medicine, 1996, 334, 413-419.	27.0	749
114	Feasibility, timing and location of adenovirus-mediated gene transfer into myocardial infarction. Journal of the American College of Cardiology, 1996, 27, 288.	2.8	0
115	The Northridge earthquake as a trigger for acute myocardial infarction. American Journal of Cardiology, 1996, 77, 1230-1232.	1.6	142
116	Calcium channel blocker debate: True lies?. Cardiovascular Drugs and Therapy, 1996, 10, 413-415.	2.6	1
117	Avoidance of Immune Response Prolongs Expression of Genes Delivered to the Adult Rat Myocardium by Replication-Defective Adenovirus. Circulation, 1996, 94, 1394-1401.	1.6	53
118	An experimental model examining the role of magnesium in the therapy of acute myocardial infarction. American Journal of Cardiology, 1995, 75, 1292-1293.	1.6	44
119	Digoxin and mortality in survivors of acute myocardial infarction: Observations in patients at low and intermediate risk. Cardiovascular Drugs and Therapy, 1995, 9, 609-617.	2.6	20
120	Digoxin and increased mortality among patients recovering from acute myocardial infarction: Importance of digoxin dose. Cardiovascular Drugs and Therapy, 1995, 9, 723-729.	2.6	31
121	Basic View on the Pathobiology of Myocardial Ischemia During Coronary Angioplasty: Implications for Cardiac Protection. Journal of Interventional Cardiology, 1995, 8, 291-299.	1.2	0
122	Improved posterobasal segment function after thrombolysis is associated with decreased incidence of significant mitral regurgitation in a first inferior myocardial infarction. Journal of the American College of Cardiology, 1995, 25, 1558-1563.	2.8	41
123	The Long-Term Prognostic Significance of High-Grade Ventricular Ectopic Activity in Survivors of Acute Myocardial Infarction. American Journal of Noninvasive Cardiology, 1994, 8, 282-288.	0.1	0
124	Failure of Captopril to Attenuate Myocardial Damage, Neutrophil Accumulation, and Mortality Following Coronary Artery Occlusion and Reperfusion in Rat. Angiology, 1994, 45, 717-724.	1.8	7
125	Absence of tachycardia during tilt test predicts failure of $\hat{1}^2$ -blocker therapy in patients with neurocardiogenic syncope. American Heart Journal, 1994, 127, 1539-1543.	2.7	47
126	Cardiogenic shock complicating acute myocardial infarction in patients without heart failure on admission: Incidence, risk factors, and outcome. American Journal of Medicine, 1993, 94, 265-273.	1.5	129

JONATHAN LEOR

#	Article	IF	CITATIONS
127	Effect of thrombolytic therapy on the evolution of significant mitral regurgitation in patients with a first inferior myocardial infarction. Journal of the American College of Cardiology, 1993, 21, 1661-1666.	2.8	53
128	Predictive value of the signal-averaged electrocardiogram for early mortality after acute myocardial infarction. Coronary Artery Disease, 1992, 3, 313-318.	0.7	2
129	latrogenic coronary arteriovenous fistula following percutaneous coronary angioplasty. American Heart Journal, 1992, 123, 784-785.	2.7	8
130	Giant U waves and associated ventricular tachycardia complicating astemizole overdose: Successful therapy with intravenous magnesium. American Journal of Medicine, 1991, 91, 94-97.	1.5	29
131	Giant Breast Hematoma Requiring Blood Transfusion: An Unusual Complication After an Echocardiographic Study During Thrombolytic Therapy. Journal of the American Society of Echocardiography, 1990, 3, 502-504.	2.8	2
132	Urgent surgical removal of a rapidly growing left ventricular thrombus following acute myocardial infarction. American Heart Journal, 1990, 119, 1199-1201.	2.7	13
133	Ventricular tachycardia after soccer ball blow to the chest: first manifestation of arrhythmogenic right ventricular dysplasia in two brothers. American Journal of Medicine, 1990, 89, 687-688.	1.5	9
134	Effects of thrombolysis on the 12-lead signal-averaged ECG in the early postinfarction period. American Heart Journal, 1990, 120, 495-502.	2.7	21
135	Pseudoakinesis: A radionuclide ventriculography sign for subacute heart rupture and tamponade early after acute myocardial infarction. American Heart Journal, 1989, 118, 612-614.	2.7	1
136	Polyglandular Autoimmune Syndrome, Type 2. Southern Medical Journal, 1989, 82, 374-376.	0.7	11
137	Amiodarone and β-adrenergic blockers: An interaction with metoprolol but not with atenolol. American Heart Journal, 1988, 116, 206-207.	2.7	18
138	Ofloxacin and Warfarin. Annals of Internal Medicine, 1988, 109, 761.	3.9	51